Indeed, although triple-negative BrCa could not be identified in our study due to the lack of information on human epidermal growth factor receptor 2 status, the prevalence of ER-/PR- was higher among women aged <55 years at diagnosis than among older ones (i.e., 45.8% and 37.6%, respectively). Here, ERBB2 is linked to invasive breast carcinoma.